Published in Lancet on November 04, 2006
Rapid Research in Diagnostics Development for TB Network (R2D2TB Network) | NCT04923958
ARDB--Antibiotic Resistance Genes Database. Nucleic Acids Res (2008) 7.82
HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet (2009) 6.96
Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis (2007) 6.41
Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med (2008) 6.17
Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med (2011) 5.06
Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One (2009) 4.92
Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest (2008) 4.41
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29
Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ (2011) 4.19
Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS (2009) 4.07
Paediatric tuberculosis. Lancet Infect Dis (2008) 3.97
XDR tuberculosis: an indicator of public-health negligence. Lancet (2006) 3.91
Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bull World Health Organ (2009) 3.77
Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science (2009) 3.73
Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa. PLoS One (2009) 3.68
Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet (2007) 3.65
Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev (2011) 3.63
A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med (2011) 3.60
Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov (2013) 3.50
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science (2009) 3.39
HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev (2011) 3.28
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J (2012) 3.00
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS (2010) 2.90
The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med (2010) 2.86
Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS (2009) 2.86
Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Res (2012) 2.81
Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2009) 2.77
Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis (2011) 2.72
TB database: an integrated platform for tuberculosis research. Nucleic Acids Res (2008) 2.71
Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis (2009) 2.66
Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis (2010) 2.65
Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med (2008) 2.63
High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb) (2009) 2.58
Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS One (2009) 2.51
Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One (2009) 2.47
Infectious disease: TB's revenge. Nature (2013) 2.37
Drug-resistant tuberculosis: a worldwide epidemic poses a new challenge. Dtsch Arztebl Int (2010) 2.36
Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science (2013) 2.34
Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother (2008) 2.33
Challenges in estimating the total burden of drug-resistant tuberculosis. Am J Respir Crit Care Med (2008) 2.33
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J (2014) 2.28
Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis (2008) 2.26
High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med (2010) 2.23
Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med (2009) 2.20
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J (2012) 2.17
Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis (2010) 2.14
Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS (2010) 2.14
Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS One (2007) 2.14
Multidrug-resistant tuberculosis. BMC Infect Dis (2008) 2.13
Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry (2007) 2.09
The infectiousness of tuberculosis patients coinfected with HIV. PLoS Med (2008) 2.08
Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A (2012) 2.05
Why is long-term therapy required to cure tuberculosis? PLoS Med (2007) 2.03
Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. Bull World Health Organ (2010) 2.03
Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A (2008) 2.03
High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis (2010) 2.03
Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int J Tuberc Lung Dis (2012) 2.03
Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol (2009) 2.01
Rates of anti-tuberculosis drug resistance in Kampala-Uganda are low and not associated with HIV infection. PLoS One (2011) 1.98
The Mycobacterium tuberculosis stress response factor SigH is required for bacterial burden as well as immunopathology in primate lungs. J Infect Dis (2012) 1.96
Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS One (2009) 1.93
The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat Med (2010) 1.91
Surgical face masks worn by patients with multidrug-resistant tuberculosis: impact on infectivity of air on a hospital ward. Am J Respir Crit Care Med (2012) 1.81
Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS One (2011) 1.79
Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis (2009) 1.78
Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. J Clin Microbiol (2010) 1.78
Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis (2011) 1.76
Averting epidemics of extensively drug-resistant tuberculosis. Proc Natl Acad Sci U S A (2009) 1.76
Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents Chemother (2008) 1.75
Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis (2014) 1.74
Has the DOTS strategy improved case finding or treatment success? An empirical assessment. PLoS One (2008) 1.74
Host-pathogen coevolution in human tuberculosis. Philos Trans R Soc Lond B Biol Sci (2012) 1.72
Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis (2013) 1.69
Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study. PLoS Med (2011) 1.68
Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis. Sci Transl Med (2012) 1.65
Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa. J Infect Dis (2012) 1.65
Upper-room ultraviolet light and negative air ionization to prevent tuberculosis transmission. PLoS Med (2009) 1.64
Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int J Tuberc Lung Dis (2014) 1.61
Extensively drug-resistant tuberculosis in a young child after travel to India. Lancet Infect Dis (2015) 1.59
Clusters of multidrug-resistant Mycobacterium tuberculosis cases, Europe. Emerg Infect Dis (2009) 1.58
Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community. PLoS One (2010) 1.57
Underreported threat of multidrug-resistant tuberculosis in Africa. Emerg Infect Dis (2008) 1.56
Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis (2012) 1.56
Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis. Am J Respir Crit Care Med (2012) 1.55
Turning off the spigot: reducing drug-resistant tuberculosis transmission in resource-limited settings. Int J Tuberc Lung Dis (2010) 1.54
Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas. PLoS One (2010) 1.53
Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis. Mol Microbiol (2008) 1.52
Clinical and microbiological features of HIV-associated tuberculous meningitis in Vietnamese adults. PLoS One (2008) 1.51
Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis (2009) 1.50
Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa. PLoS One (2011) 1.50
Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother (2009) 1.47
Transmission of drug-susceptible and drug-resistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rollouts. Clin Infect Dis (2010) 1.47
Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med (2007) 1.46
The tuberculosis challenge in a rural South African HIV programme. BMC Infect Dis (2010) 1.46
Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Curr Opin Infect Dis (2009) 1.46
Evaluation of microscopic observation drug susceptibility assay for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol (2007) 1.45
Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis (2008) 1.43
Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother (2010) 1.43
Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses. PLoS One (2009) 1.43
Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med (2010) 10.90
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med (2011) 5.31
The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis (2002) 4.43
Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis (2007) 3.74
Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa. PLoS One (2009) 3.68
Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet (2007) 3.65
Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis (2008) 3.33
Comparative performance of private and public healthcare systems in low- and middle-income countries: a systematic review. PLoS Med (2012) 2.68
Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. J Infect Dis (2012) 2.42
Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med (2012) 2.40
Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8. J Infect Dis (2004) 2.27
Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis (2002) 2.14
Interrelationships among human immunodeficiency virus type 1 infection, bacterial vaginosis, trichomoniasis, and the presence of yeasts. J Infect Dis (2001) 2.13
Lack of association between the nasopharyngeal carriage of Streptococcus pneumoniae and Staphylococcus aureus in HIV-1-infected South African children. J Infect Dis (2006) 2.10
Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS (2008) 2.02
Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study. J Acquir Immune Defic Syndr (2009) 2.01
Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS (2005) 1.88
Averting epidemics of extensively drug-resistant tuberculosis. Proc Natl Acad Sci U S A (2009) 1.76
Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. J Infect Dis (2007) 1.73
Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial. J Acquir Immune Defic Syndr (2008) 1.70
Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa. J Infect Dis (2012) 1.65
The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clin Infect Dis (2005) 1.62
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother (2006) 1.58
Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community. PLoS One (2010) 1.57
Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis (2006) 1.52
Computer-based intervention in HIV clinical care setting improves antiretroviral adherence: the LifeWindows Project. AIDS Behav (2011) 1.49
Transmission of drug-susceptible and drug-resistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rollouts. Clin Infect Dis (2010) 1.47
Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Curr Opin Infect Dis (2009) 1.46
Emergence of fluoroquinolone-resistant Streptococcus pneumoniae in a South African child in a tuberculosis treatment facility. Pediatr Infect Dis J (2003) 1.44
Implementing antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating HIV and tuberculosis care. AIDS (2004) 1.42
A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. J Acquir Immune Defic Syndr (2004) 1.42
Tuberculosis and HIV-needed: a new paradigm for the control and management of linked epidemics. MedGenMed (2007) 1.41
Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J Infect Dis (2010) 1.39
Association between HIV-1 infection, the etiology of genital ulcer disease, and response to syndromic management. Sex Transm Dis (2003) 1.36
Association between HIV and subpreputial penile wetness in uncircumcised men in South Africa. J Acquir Immune Defic Syndr (2006) 1.36
Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa. Emerg Infect Dis (2011) 1.35
The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med (2012) 1.32
Spread of extensively drug-resistant tuberculosis in KwaZulu-Natal province, South Africa. PLoS One (2011) 1.30
The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis (2003) 1.28
Extensively drug-resistant tuberculosis: a new face to an old pathogen. Annu Rev Med (2009) 1.24
Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS (2004) 1.23
Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis (2006) 1.22
Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend (2007) 1.21
Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial. AIDS (2010) 1.20
Rapid diagnosis of tuberculosis and multidrug resistance by the microscopic-observation drug-susceptibility assay. Am J Respir Crit Care Med (2011) 1.20
Prevalence of methicillin-resistant Staphylococcus aureus nasal carriage among hospitalised patients with tuberculosis in rural Kwazulu-Natal. S Afr Med J (2011) 1.19
Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries. Clin Infect Dis (2004) 1.18
Global health delivery 2.0: using open-access technologies for transparency and operations research. PLoS Med (2009) 1.16
φ(2)GFP10, a high-intensity fluorophage, enables detection and rapid drug susceptibility testing of Mycobacterium tuberculosis directly from sputum samples. J Clin Microbiol (2012) 1.13
Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. J Clin Microbiol (2010) 1.11
Use of total lymphocyte count for monitoring response to antiretroviral therapy. Clin Infect Dis (2003) 1.10
HAART for hospital health care workers--an innovative programme. S Afr Med J (2004) 1.07
Discovery of the function of the heart and circulation of blood. Cardiovasc J Afr (2009) 1.06
Molecular diagnosis of lymphogranuloma venereum in patients with genital ulcer disease. J Clin Microbiol (2005) 1.06
Blood cultures for the diagnosis of multidrug-resistant and extensively drug-resistant tuberculosis among HIV-infected patients from rural South Africa: a cross-sectional study. BMC Infect Dis (2010) 1.05
Implementing a systems-oriented morbidity and mortality conference in remote rural Nepal for quality improvement. BMJ Qual Saf (2011) 1.05
HIV drug resistance and HIV transmission risk behaviors among active injection drug users. J Acquir Immune Defic Syndr (2005) 1.05
Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proc Natl Acad Sci U S A (2012) 1.04
The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life. J Acquir Immune Defic Syndr (2008) 1.04
Mild-to-moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individuals. Clin Infect Dis (2008) 1.01
Molecular epidemiology of recently emergent ciprofloxacin-resistant Neisseria gonorrhoeae in South Africa. Sex Transm Dis (2006) 0.99
Complexity in mathematical models of public health policies: a guide for consumers of models. PLoS Med (2013) 0.98
Transmission of tuberculosis in resource-limited settings. Curr HIV/AIDS Rep (2013) 0.98
Minimal diversity of drug-resistant Mycobacterium tuberculosis strains, South Africa. Emerg Infect Dis (2014) 0.97
Crossing the quality chasm in resource-limited settings. Global Health (2012) 0.96
HIV prevention counseling intervention delivered during routine clinical care reduces HIV risk behavior in HIV-infected South Africans receiving antiretroviral therapy: the Izindlela Zokuphila/Options for Health randomized trial. J Acquir Immune Defic Syndr (2014) 0.93
Multicenter prospective study on the burden of rotavirus gastroenteritis in Turkey, 2005-2006: a hospital-based study. J Infect Dis (2009) 0.92
Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir. Am J Addict (2004) 0.92
Short communication: Transmitted drug resistance and molecular epidemiology in antiretroviral naive HIV type 1-infected patients in Rhode Island. AIDS Res Hum Retroviruses (2010) 0.92
Influence of HIV-1 coinfection on effective management of abnormal vaginal discharge. Sex Transm Dis (2003) 0.92
Ciprofloxacin-resistant gonorrhoea in South Africa. Lancet (2005) 0.92
A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care. MedGenMed (2006) 0.91
Adhesion to and invasion of pulmonary epithelial cells by the F15/LAM4/KZN and Beijing strains of Mycobacterium tuberculosis. J Med Microbiol (2010) 0.90
Pyrido[1,2-a]benzimidazole-based agents active against tuberculosis (TB), multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB. ChemMedChem (2011) 0.90
Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. Am J Addict (2006) 0.90
Developing a peer-mentor program for medical students. Teach Learn Med (2013) 0.90
Retrospective study on the critical factors for retaining patients on antiretroviral therapy in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr (2010) 0.89
Strengthening Nepal's Female Community Health Volunteer network: a qualitative study of experiences at two years. BMC Health Serv Res (2014) 0.89
Probable mother to infant transmission of Pneumocystis jiroveci from an HIV-infected woman to her HIV-uninfected infant. AIDS (2005) 0.88
The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. S Afr Med J (2010) 0.85